This video requires your consent.

MOVIVA®

Turn down the food noise

MOVIVA® is the innovative, minimally invasive endoscopic solution for gastric mucosal ablation (GMA) in the fundus. It reduces the patient's hunger feeling and, when combined with Endoscopic Sleeve Gastroplasty (ESG), GMA can yield weight loss results comparable to traditional bariatric surgery.

“Minimally invasive endoscopic techniques that target appetite regulation through precise ablation of the gastric fundus offer patients an effective pathway to weight loss without the risks associated with surgery. MOVIVA®’s innovative injection and ablation capabilities simplify the GMA procedure and could set a new standard in endoscopic bariatric care.”

Prof. Ivo Boskoski
Prof. Ivo Boskoski

Rome, Italy

“Combining GMA with ESG represents one of the most promising breakthroughs in non-surgical weight loss treatment. In our early clinical trials, this dual approach achieved total body weight loss of 23 to 24 percent - comparable to surgical sleeve gastrectomy, but without the need for surgery. Patients consistently report greater control over hunger, reduced cravings, and an improved relationship with food. These results are not just clinically significant - they are potentially life-changing.”

Christopher McGowan
Christopher McGowan

MD, Charlotte, U.S.

GMA – How it works

The GMA procedure involves ablating the mucosa of the gastric fundus. This reduces the production of ghrelin - the so-called hunger hormone, resulting in less hunger and fewer cravings. At the same time, the ablation of tissue leads to a shrinking of the fundus.

No video found or Vimeo API error.

No video found or Vimeo API error.

GMA procedure with MOVIVA®

Endoscopic ablation of the gastric fundus with MOVIVA®: First the distal fundal border is marked with dots using short activations of APC.

The area to be ablated is elevated with saline solution by means of high-pressure needle-free injection and then ablated with argon plasma coagulation (APC). These two steps are repeated until the entire area has been ablated.

When GMA is combined with ESG, the approach achieves weight loss outcomes comparable to vertical sleeve gastrectomy (VSG), while being less invasive.

Download our E-Flyer

A new addition to your treatment portfolio

MOVIVA® provides a viable alternative for patients who fear the side effects and risks of bariatric surgical interventions.

Start your clinical journey with MOVIVA® today

To support reliable results during GMA with MOVIVA®, we offer dedicated training courses. 
These are available in various countries and regions.

Book your course now!

Scientific information

Publication
Gadi SR, et al. (2026) “Gastric fundal mucosal ablation followed by endoscopic sleeve gastroplasty in adults with obesity: a first-in-human two-phase pilot clinical trial.” Endoscopy, 2026. 

Objective
Endoscopic sleeve gastroplasty (ESG) achieves moderate weight loss but is less effective than surgical vertical sleeve gastrectomy, partly due to preservation of the gastric fundus. Gastric fundal mucosal ablation (GFMA) has been shown to reduce ghrelin levels and appetite.
This study aimed to evaluate the effectiveness and safety of sequential GFMA followed by ESG in adults with obesity, with the hypothesis that the combined approach may improve weight loss outcomes.

Conclusion
Sequential GFMA followed by ESG is safe, feasible, and highly effective, resulting in substantial and clinically meaningful weight loss. The combined approach targets both hormonal (ghrelin) and mechanical/visceroceptive pathways of appetite regulation, potentially overcoming limitations of ESG alone. This strategy represents a promising advancement in endoscopic obesity treatment, though larger and long-term studies are required for validation

More information

Publication
Boškoski Ivo et al. (2026). “Combined gastric mucosal ablation of the fundus using a new hybrid device with endoscopic sleeve gastroplasty for obesity.” Endoscopy 2026; 58: E141–E142 

Objective
The case report describes a novel combined endoscopic approach for obesity treatment that integrates endoscopic sleeve gastroplasty (ESG) with gastric mucosal ablation (GMA) of the fundus, aiming to enhance weight loss through both mechanical restriction and hormonal modulation. 

Conclusion
The combined ESG + GMA approach demonstrates feasibility and safety and shows promising short-term weight loss outcomes. However, larger studies are required to confirm its long-term efficacy and safety.

 

More information

Publication
McGowan, C. E., et al. (2025). “Combination gastric fundus mucosal ablation and endoscopic sleeve gastroplasty: Results from two first-inhuman studies.” Gastrointestinal Endoscopy, Volume 101, Issue 5, S58.

Objective
To evaluate the safety and efficacy of combining Gastric Fundus Mucosal Ablation (GFMA) with Endoscopic Sleeve Gastroplasty (ESG) as a non-surgical outpatient procedure for weight loss in adults with obesity.

Conclusion
The integration of GFMA with ESG offers a promising, minimally invasive alternative to surgical weight loss procedures, delivering comparable efficacy with a favorable safety profile.

 

More information

Publication

De Siena et al. (2025). “A pilot study to evaluate the efficacy and safety of Gastric Mucosal Ablation (GMA) of the fundus with Hybrid Argon Plasma Coagulation (HybridAPC) combined with Endoscopic Sleeve Gastroplasty (ESG) in obese patients” ESGE Days 2025

More information

Publication

Maselli, Daniel B et al. (2024) “Endoscopic Gastric Fundal Mucosal Ablation Induces Weight Loss in Adults With Obesity.” Gastroenterology vol. 167,7 (2024): 1457-1459.e3.

More information

MOVIVA® – Hybrid technology for GMA

MOVIVA® is an advanced hybrid instrument designed for GMA. It combines two key functions in one product:

  1. Injection of fluid to form a submucosal cushion that protects deeper tissue layers from thermal injury
  2. Superficial thermal ablation of the mucosa using APC.
    MOVIVA® is equipped with the dedicated moveAPD® mode, delivering broad and consistent APC.

Stay up to date!

Questions?

Do you have questions about MOVIVA® or GMA?
Reach out to us - we are happy to support you!

Contact us